After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...
PRINCETON, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech” or the "Company”), a late-stage immunotherapy company focused on transforming how the ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, ...
Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback